Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials

August 14, 2024

An experimental malaria vaccine, tested in Malian adults, showed sustained protection against parasite infection and clinical malaria over two years without a booster dose. It also significantly protected women from malaria during pregnancy, suggesting potential for improved prevention strategies.

Related Clinical Trials

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali

Highlighted Terms

U.S. Department of Health and Human Services National Institute of Allergy and Infectious Diseases (NIAID)Malaria Research and Training Center (MRTC)malaria PfSPZ Vaccine Sanaria Inc.National Institutes of Health (NIH)NCT03989102 University of Sciences, Techniques and Technologies, Bamako (USTTB), Mali NCT03510481

Related News

drugs.com

Candidate Malaria Vaccine Provides Lasting Protection in NIH-Sponsored Trials